Drug Profile
APO 010 companion diagnostic - Allarity Therapeutics
Alternative Names: APO010 DRP™Latest Information Update: 19 Feb 2022
Price :
$50
*
At a glance
- Originator Oncology Venture
- Developer Allarity Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 19 Feb 2022 No development reported - Phase-II for Multiple myeloma (Diagnosis) in Denmark (unspecified route)
- 07 Oct 2020 Oncology Venture A/S is now called Allarity Therapeutics
- 24 Aug 2018 Medical Prognosis Institute merged with Oncology Venture and the former changed its name to Oncology Venture A/S